Pleural effusion due to imatinib: Case report İmatinib'e baģli plevral efüzyon

Akpinar S., Uçar N., Akpinar E., Dursun A. B., Örsel O., Şipit T.

Turkiye Klinikleri Journal of Medical Sciences, vol.29, no.1, pp.258-262, 2009 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 1
  • Publication Date: 2009
  • Journal Name: Turkiye Klinikleri Journal of Medical Sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.258-262
  • Keywords: Imatinib, Leukemia, myeloid, chronic-phase, Pleural effusion
  • Lokman Hekim University Affiliated: No


One of the most important side effects of tyrosine kinase inhibitors, which are the first line treatment options in chronic myleoid leukemia (CML), is lung abnormalities among which pleural effusion is the most important. A 25-year-old female patient with CML for 10 months who has been treated with imatinib was admitted due to shortness of breath and back pain. Warfarin was started three months ago with the diagnosis of pulmonary thromboembolism. Chest X-ray revealed bilateral pleural effusion. Thorax computerized tomography angiography performed in order to exclude recurrent pulmonary thromboembolism revealed thrombosis. Thorasynthesis yielded an exudative pleural fluid with a predominance of lymphocytes. The patient improved radiologically and clinically improvement after stopping imatinib, while the etiology of pleurisy was being investigated. This interesting case was discussed reviewing the literature. Copyright © 2009 by Türkiye Klinikleri.